Login to Your Account

Clinic Roundup

Wednesday, July 3, 2013
• Immunomedics Inc., of Morris Plains, N.J., reported findings from a Phase Ib study with 90Y-clivatuzumab in patients with metastatic pancreatic cancer who had received at least two prior treatments.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription